467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

467.05

-1.1%↓

SANES

10.262

+0.55%↑

SAF

272.1

+0.67%↑

BBVA

18.665

+0.76%↑

BNP

89.84

+0.99%↑

Home・Akciju saraksts・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Slēgts

SektorsFinanšu

159.8 -1.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

159.5

Max

165.2

Galvenie mērījumi
By Trading Economics
Ienākumi	-17M 47M
Pārdošana	67M 772M
P/E Sektora vidējais	68.388 39.62
Dividenžu ienesīgums	0.37
Peļņas marža	6.125
Darbinieki	9,753
EBITDA	-19M 199M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+43.56% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.37% 4.52%
Nākamie ieņēmumi	2026. g. 23. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-55M 18B
Iepriekšējā atvēršanas cena	161.28
Iepriekšējā slēgšanas cena	159.8

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

202.7 / 211.7 Atbalsts un pretestība

Sartorius Stedim Biotech. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026. g. 27. apr. 23:08 UTC

Peļņas

Galvenie tirgus virzītāji

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026. g. 27. apr. 23:48 UTC

Tirgus saruna

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 27. apr. 23:42 UTC

Tirgus saruna

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026. g. 27. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026. g. 27. apr. 23:30 UTC

Tirgus saruna

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026. g. 27. apr. 23:08 UTC

Tirgus saruna

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026. g. 27. apr. 22:42 UTC

Tirgus saruna

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026. g. 27. apr. 22:10 UTC

Peļņas

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026. g. 27. apr. 21:56 UTC

Peļņas

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026. g. 27. apr. 21:44 UTC

Peļņas

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026. g. 27. apr. 21:43 UTC

Peļņas

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. apr. 20:39 UTC

Peļņas

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Salīdzinājums

Cenas izmaiņa

Sartorius Stedim Biotech. Prognoze

Cenas mērķis

By TipRanks

43.56% augšup

Prognoze 12 mēnešiem

Vidējais 233 EUR 43.56%

Augstākais 262 EUR

Zemākais 210 EUR

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sartorius Stedim Biotech. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Sartorius Stedim Biotech. — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

202.7 / 211.7Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.